arrow
V

Vı́ctor Vargas

universidad autonoma de barcelona
H指数:61
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Factors associated with progression, resolution and mortality of patients with overt hepatic encephalopathy

与显性肝性脑病患者进展、缓解和死亡率相关的因素

2025-11-070
PRE
Real-world use of terlipressin in cirrhosis and acute kidney injury: frequent use beyond hepatorenal syndrome

特利加压素在肝硬化及急性肾损伤中的实际应用:超越肝肾综合征的频繁使用

2025-09-080
OAAI
Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease

靶向抑制致病共生菌毒力因子可缓解酒精性肝病

2025-05-280
PRE
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

频繁的ATP7B突变的低外显率解释了威尔逊病的低患病率。现实生活中的注册经验教训。

2025-02-010
PRE
Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis
2024-09-250
PRE
Development and external validation of a model to predict multidrug-resistant bacterial infections in patients with cirrhosis
2024-08-152
PRE
Relationship between updated MELD and prognosis in alcohol-associated hepatitis: Opportunities for more efficient trial design
2024-08-010
OAAI
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study

人工智能生成的模型预测酒精相关性肝炎的90天生存率: 一项全球队列研究

2024-04-123
PRE
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Elafibranor在原发性胆汁性胆管炎中的疗效和安全性

2024-02-2945
PRE
Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis
2024-02-201
PRE
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections-Results from the ICA Global Study (EABCIR-Global Study)
2023-12-014
PRE
MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis
2023-08-0112
OAAI
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
2023-04-0645
OAAI